EU signs deal with Gilead on access to remdesivir

Wednesday, 29. July 2020 12:13

The European Commission announced on Wednesday that it signed an agreement with Gilead Sciences to secure access to its drug remdesivir used to treat COVID-19.

The Commission stressed that the deal worth €63 million will "ensure treatment from early August for approximately 30,000 patients in the EU and the UK with severe coronavirus symptoms."

Earlier this month, the European Union authorized the use of remdesivir for treating COVID-19.

Related Links: Gilead Sciences Inc.
Breaking the News / NP